Chapters

Transcript

Video

What are the current dosages for glucocorticoid therapy and what markers are currently followed to assess adequacy of therapy? And why do clinicians have an incentive to lower glucocorticoid dose in persons with CAH?

What are the current dosages for glucocorticoid therapy and what markers are currently followed to assess adequacy of therapy? And why do clinicians have an incentive to lower glucocorticoid dose in persons with CAH?


Created by

CMEducation Resources | iQ&A Congenital Adrenal Hyperplasia (CAH) Medical Intelligence Zone 

Presenter

Patricia Fechner, MD

Patricia Fechner, MD

Medical Director, DSD Program
Medical Director, CAH Program
Co-Director, Turner Syndrome Clinic
Seattle Children’s Hospital
Professor of Pediatrics
University of Washington School of Medicine
Seattle, WA